# An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

> **NCT00357786** · PHASE1 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 3 (—)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Replagal agalsidase alfa
- **DRUG:** Replagal

## Key facts

- **NCT ID:** NCT00357786
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2008-12
- **Final completion:** —
- **Target enrollment:** 3 (—)
- **Last updated:** 2011-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357786, "An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00357786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*